Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing

The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is due to the high rates of transmission by individuals who are asymptomatic at the time of transmission. Frequent, widespread testing of the asymptomatic population for SARS-CoV-2 is essential to suppress viral transmission and is a key element in safely reopening society. Despite increases in testing capacity, multiple challenges remain in deploying traditional reverse transcription and quantitative PCR (RT-qPCR) tests at the scale required for population screening of asymptomatic individuals. We have developed SwabSeq, a high-throughput testing platform for SARS-CoV-2 that uses next-generation sequencing as a readout. SwabSeq employs sample-specific molecular barcodes to enable thousands of samples to be combined and simultaneously analyzed for the presence or absence of SARS-CoV-2 in a single run. Importantly, SwabSeq incorporates an in vitro RNA standard that mimics the viral amplicon, but can be distinguished by sequencing. This standard allows for end-point rather than quantitative PCR, improves quantitation, reduces requirements for automation and sample-to-sample normalization, enables purification-free detection, and gives better ability to call true negatives. We show that SwabSeq can test nasal and oral specimens for SARS-CoV-2 with or without RNA extraction while maintaining analytical sensitivity better than or comparable to that of fluorescence-based RT-qPCR tests. SwabSeq is simple, sensitive, flexible, rapidly scalable, inexpensive enough to test widely and frequently, and can provide a turn around time of 12 to 24 hours.

[1]  Robert Gentleman,et al.  ShortRead: a bioconductor package for input, quality assessment and exploration of high-throughput sequence data , 2009, Bioinform..

[2]  Anne Kimball,et al.  Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility — King County, Washington, March 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[3]  B. Faircloth,et al.  Primer3—new capabilities and interfaces , 2012, Nucleic acids research.

[4]  E. M. Jones,et al.  A Scalable, Multiplexed Assay for Decoding GPCR-Ligand Interactions with RNA Sequencing. , 2019, Cell systems.

[5]  L. Pachter,et al.  Fast and accurate diagnostics from highly multiplexed sequencing assays , 2020, medRxiv.

[6]  Mark P. J. van der Loo,et al.  The stringdist Package for Approximate String Matching , 2014, R J..

[7]  Michael K. Slevin,et al.  Unique, dual-indexed sequencing adapters with UMIs effectively eliminate index cross-talk and significantly improve sensitivity of massively parallel sequencing , 2018, BMC Genomics.

[8]  Li Yujian,et al.  A Normalized Levenshtein Distance Metric , 2007, IEEE Transactions on Pattern Analysis and Machine Intelligence.

[9]  J. A. Hay,et al.  Test sensitivity is secondary to frequency and turnaround time for COVID-19 surveillance , 2020, medRxiv.

[10]  Tristan W. Clark,et al.  Diagnostic accuracy of the FebriDx host response point-of-care test in patients hospitalised with suspected COVID-19 , 2020, Journal of Infection.

[11]  Lior Pachter,et al.  Modular and efficient pre-processing of single-cell RNA-seq , 2019, bioRxiv.

[12]  A. Danchin,et al.  The Severe Acute Respiratory Syndrome , 2003 .

[13]  Martin D. Burke,et al.  Saliva-Based Molecular Testing for SARS-CoV-2 that Bypasses RNA Extraction , 2020, bioRxiv.

[14]  D. Havlir,et al.  Asymptomatic Transmission, the Achilles’ Heel of Current Strategies to Control Covid-19 , 2020, The New England journal of medicine.

[15]  Rochelle P. Walensky,et al.  Assessment of SARS-CoV-2 Screening Strategies to Permit the Safe Reopening of College Campuses in the United States , 2020, JAMA network open.

[16]  S. Bhatt,et al.  Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo’ , 2020, Nature.

[17]  John T Brooks,et al.  Evidence Supporting Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic , 2020, Emerging infectious diseases.

[18]  Cecilia Cheng,et al.  Perception of benefits and costs during SARS outbreak: An 18-month prospective study. , 2006, Journal of consulting and clinical psychology.

[19]  Francesco Vezzi,et al.  Index hopping on the Illumina HiseqX platform and its consequences for ancient DNA studies , 2018, Molecular ecology resources.

[20]  Michael A Quail,et al.  Improved Protocols for the Illumina Genome Analyzer Sequencing System , 2009, Current protocols in human genetics.

[21]  Sharon L. Grim,et al.  Analysis, Optimization and Verification of Illumina-Generated 16S rRNA Gene Amplicon Surveys , 2014, PloS one.